[EN] HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOPYRIDINE À SUBSTITUTION HÉTÉROARYLE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2016210037A1
公开(公告)日:2016-12-29
Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; A is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 Ra; and R3, Ra, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
公开的是Formula (I)的化合物或其盐,其中:HET是从咪唑并[1,2-b]吡啶基和吡唑并[1,5-a]嘧啶基中选择的杂芳基,其中所述杂芳基通过杂芳基中的一个碳环原子连接到Formula (I)的吡啶基,并且所述杂芳基被取代为零至2个Rb;A是吡唑基、咪唑基或三唑基,每个取代为零或1个Ra;R3、Ra和Rb在此处定义。还公开了将这些化合物用作IRAK4调节剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症性和自身免疫性疾病,或治疗癌症方面是有用的。